BioNTech SE (22UA) - Total Liabilities
Based on the latest financial reports, BioNTech SE (22UA) has total liabilities worth €2.38 Billion EUR (≈ $2.78 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BioNTech SE (22UA) net asset momentum to track the company's year-over-year net asset growth rate.
BioNTech SE - Total Liabilities Trend (2016–2025)
This chart illustrates how BioNTech SE's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of BioNTech SE to measure how efficiently the company converts operating cash flow to free cash.
BioNTech SE Competitors by Total Liabilities
The table below lists competitors of BioNTech SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHINA SHENHUA EN.A ADR/4
F:IKFC
|
Germany | €227.40 Billion |
|
Northern Star Resources Ltd
AU:NST
|
Australia | AU$5.46 Billion |
|
MKS Instruments Inc
NASDAQ:MKSI
|
USA | $5.92 Billion |
|
Amer Sports, Inc.
NYSE:AS
|
USA | $4.24 Billion |
|
Incyte Corporation
NASDAQ:INCY
|
USA | $1.79 Billion |
|
LyondellBasell Industries NV
NYSE:LYB
|
USA | $23.79 Billion |
|
Snap-On Inc
NYSE:SNA
|
USA | $2.46 Billion |
|
MTN Group Ltd
JSE:MTN
|
South Africa | ZAC328.98 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down BioNTech SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BioNTech SE stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNTech SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNTech SE (2016–2025)
The table below shows the annual total liabilities of BioNTech SE from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.76 Billion ≈ $3.23 Billion |
-11.36% |
| 2024-12-31 | €3.12 Billion ≈ $3.65 Billion |
+12.98% |
| 2023-12-31 | €2.76 Billion ≈ $3.23 Billion |
-14.37% |
| 2022-12-31 | €3.22 Billion ≈ $3.77 Billion |
-18.13% |
| 2021-12-31 | €3.94 Billion ≈ $4.60 Billion |
+315.84% |
| 2020-12-31 | €946.77 Million ≈ $1.11 Billion |
+211.28% |
| 2019-12-31 | €304.15 Million ≈ $355.59 Million |
-21.20% |
| 2018-12-31 | €385.99 Million ≈ $451.26 Million |
-8.73% |
| 2017-12-31 | €422.92 Million ≈ $494.44 Million |
+18.10% |
| 2016-12-31 | €358.10 Million ≈ $418.66 Million |
-- |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic tr… Read more